Business Context and Reporting Period
This Form 8-K Current Report was filed by Recursion Pharmaceuticals, Inc. (RXRX) on June 9, 2022, covering events occurring on June 7, 2022. The company is a Delaware corporation incorporated as an emerging growth company, with its principal executive offices located in Salt Lake City, Utah.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
The primary material change reported is a leadership transition within the medical leadership team:
- Departure: Ramona Doyle, MD, ended her employment as Chief Medical Officer (CMO) on June 7, 2022.
- Appointment: Shafique Virani, MD FRCS, was appointed as interim CMO on June 7, 2022.
- Continued Role: Dr. Virani continues to serve as the Company's Chief Business Officer, a role he has held since December 2020.
Management Commentary and Risks
Dr. Virani brings significant prior experience to the interim role, having previously served as interim CMO for Recursion from March 2020 to December 2020. His background includes serving as CEO of Navire Pharma and CoA Therapeutics (subsidiaries of BridgeBio LLC) and holding senior business development roles at Roche and Genentech. The filing explicitly states there are no undisclosed arrangements, family relationships, or related person transactions involving Dr. Virani that require disclosure under Regulation S-K.
Investor Verification Checklist
- Verify the timeline for the search for a permanent Chief Medical Officer to replace Dr. Doyle.
- Review Dr. Virani's dual responsibilities as interim CMO and Chief Business Officer for potential resource allocation impacts.
- Confirm if the departure of Dr. Doyle was voluntary or part of a broader strategic restructuring.
- Check subsequent filings for any changes to the company's drug development pipeline resulting from this leadership change.